INVEGA SUSTENNA® is approved for the treatment of schizoaffective disorder

INVEGA SUSTENNA® Provided Significant Symptom Improvement in PANSS Total Scores in a Short-term Study1,2

Significant schizophrenia symptom control1,2
A graph illustrating INVEGA SUSTENNA® PANSS Study

*P≤0.034 (all doses vs placebo at endpoint).

No oral supplementation from day 1 of initiation.1,2

PANSS=Positive and Negative Syndrome Scale.

NOTE: Two deltoid intramuscular injections of 234 mg (on day 1) and 156 mg (on day 8) are the recommended initiation doses for INVEGA SUSTENNA®.1

Demonstrated change in PANSS subscales (short-term study)2
A graph illustrating INVEGA SUSTENNA® efficacy results for change in PANSS score

PANSS=Positive and Negative Syndrome Scale.

The study was not powered to draw conclusions for individual factors of the PANSS.

Indicated for the treatment of schizophrenia.

The full constellation of symptoms and the relevant diagnostic criteria should be consulted and are available in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5®, or current version), where applicable.

PANSS Subscales3

PANSS is a 30-item scale that measures positive and negative symptoms of schizophrenia, as well as general psychopathology.1,3 The PANSS subscales can be used to assess symptom changes.3

The 30-item PANSS consists of3 :

  • 7-item positive scale, measuring symptoms added to normal mental status
  • 7-item negative scale, assessing features absent from normal mental status
  • 16-item general psychopathology scale, measuring the overall severity of schizophrenia

Positive scale3:

  • Delusions
  • Conceptual disorganization
  • Hallucinatory behavior
  • Excitement
  • Grandiosity
  • Suspiciousness
  • Hostility

Negative scale3:

  • Blunted affect
  • Emotional withdrawal
  • Poor rapport
  • Passive-apathetic social withdrawal
  • Difficulty in abstract thinking
  • Lack of spontaneity and flow of conversation
  • Stereotyped thinking

General psychopathology scale3:

  • Somatic concern
  • Anxiety
  • Guilt feelings
  • Tension
  • Mannerisms and posturing
  • Depression
  • Motor retardation
  • Uncooperativeness
  • Unusual thought content
  • Disorientation
  • Poor attention
  • Lack of judgment and insight
  • Disturbance of volition
  • Poor impulse control
  • Preoccupation
  • Active social avoidance

Results from a double-blind, randomized, placebo-controlled, fixed-dose, 13-week study of adult patients experiencing an acute exacerbation of schizophrenia. Patients were randomized to receive placebo or a 234-mg deltoid injection initiation dose on day 1, followed by a 39-mg, 156-mg, or 234-mg dose in either the deltoid or gluteal muscle on day 8, and once monthly thereafter.1,2

Mean PANSS Total Scores Remained Stable for Patients on INVEGA SUSTENNA® While Significantly Worsening for Patients on Placebo During a Longer-term Study4

Secondary endpoint:
Change in mean PANSS total score over time4
A graph illustrating INVEGA SUSTENNA® efficacy results for change in the mean of PANSS score over time

Median duration of total exposure in the INVEGA SUSTENNA® arm was 13 months.1

The study was not powered to draw conclusions for individual factors of the PANSS.

Indicated for the treatment of schizophrenia.

The full constellation of symptoms and the relevant diagnostic criteria should be consulted and are available in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5®, or current version), where applicable.

References: 1. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2018. 2. Pandina GJ, Lindenmayer J-P, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3):235-244. 3. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. 4. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-117.

Content area 1.2